Christopher T. Su
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christopher T. Su has a total of 254 co-authors. Here are the top co-authors by number of shared publications:
Rana R. McKay
7 shared publications- Vadim S. Koshkin
Division of Hematology and Oncology, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA
7 shared publications Amanda Nizam
6 shared publications- Clara Hwang
Department of Internal Medicine, Division of Hematology and Oncology Henry Ford Health Detroit Michigan USA
6 shared publications - Dimpy P. Shah
Mays Cancer Center, The University of Texas Health San Antonio MD Anderson Cancer Center
6 shared publications - Jeremy Lyle Warner
Legorreta Cancer Center, Brown University, Providence, RI
6 shared publications
Latest Publications
- 8 April 2026
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 72 (1) , e1-e9
Palliative Care for Immigrants With Cancer in the United States: A Roadmap to Equitable Care
- 8 April 2026
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 72 (1) , e1-e9
Palliative Care for Immigrants With Cancer in the United States: A Roadmap to Equitable Care
- 20 November 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (4) , e483-e491.e2
Association of Personal Credit Data With Financial Hardship and Treatment Outcomes in Patients With Multiple Myeloma
- 20 November 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (4) , e483-e491.e2
Association of Personal Credit Data With Financial Hardship and Treatment Outcomes in Patients With Multiple Myeloma
- Open Access
- 24 July 2025
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (9)
Association of Social Vulnerability Index and Chimeric Antigen Receptor T-Cell Therapy Administration, 2018-2023
Chimeric antigen receptor T-cell (CAR T) therapy for patients with relapsed/refractory hematologic malignancies demands numerous visits which may pose challenges for patients with lower socioeconomic status (SES). The Centers for Disease Control and Prevention publishes the Social Vulnerability Index (SVI) which summarizes area-level SES factors that predict how residents respond to stressors, including a new cancer diagnosis. We used the nationwide MarketScan commercial and Medicare insurance claims database to analyze the association between SVI and CAR T therapy completion. We performed multivariable logistic regressions (adjusting for patient-level covariates) and found that patients with hematologic malignancies residing in areas of higher SVI (lower SES) have decreased odds of CAR T therapy completion (OR 0.84 for leukemia, P = 0.02; OR 0.72 for lymphoma, P < 0.001; OR 0.70 for myeloma, P < 0.001). Therefore, strategies to mitigate CAR T disparities may be focused on patients living in areas with higher SVI.
- 24 July 2025
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (9)
Open AccessAssociation of Social Vulnerability Index and Chimeric Antigen Receptor T-Cell Therapy Administration, 2018-2023
Chimeric antigen receptor T-cell (CAR T) therapy for patients with relapsed/refractory hematologic malignancies demands numerous visits which may pose challenges for patients with lower socioeconomic status (SES). The Centers for Disease Control and Prevention publishes the Social Vulnerability Index (SVI) which summarizes area-level SES factors that predict how residents respond to stressors, including a new cancer diagnosis. We used the nationwide MarketScan commercial and Medicare insurance claims database to analyze the association between SVI and CAR T therapy completion. We performed multivariable logistic regressions (adjusting for patient-level covariates) and found that patients with hematologic malignancies residing in areas of higher SVI (lower SES) have decreased odds of CAR T therapy completion (OR 0.84 for leukemia, P = 0.02; OR 0.72 for lymphoma, P < 0.001; OR 0.70 for myeloma, P < 0.001). Therefore, strategies to mitigate CAR T disparities may be focused on patients living in areas with higher SVI.
- 23 July 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (12) , 959-972
Assessing Social Determinants of Health in Transplantation and CAR-T Recipients: Expert Panel Recommendations from the Survivorship Special Interest Group of ASTCT
- 23 July 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (12) , 959-972
Assessing Social Determinants of Health in Transplantation and CAR-T Recipients: Expert Panel Recommendations from the Survivorship Special Interest Group of ASTCT
- 28 March 2025
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 23 (3.5)
HSR25-184: Association of Chimeric Antigen Receptor T-Cell Therapy and Social Vulnerability Index: A National View of Care Delivery Patterns
"HSR25-184: Association of Chimeric Antigen Receptor T-Cell Therapy and Social Vulnerability Index: A National View of Care Delivery Patterns" published on 28 Mar 2025 by National Comprehensive Cancer Network.
- 28 March 2025
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 23 (3.5)
HSR25-184: Association of Chimeric Antigen Receptor T-Cell Therapy and Social Vulnerability Index: A National View of Care Delivery Patterns
"HSR25-184: Association of Chimeric Antigen Receptor T-Cell Therapy and Social Vulnerability Index: A National View of Care Delivery Patterns" published on 28 Mar 2025 by National Comprehensive Cancer Network.
- 15 May 2024
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 65 (10) , 1418-1429
Mitigating time toxicity in lymphoma and multiple myeloma
The concept of time toxicity in oncology refers to the presence of frequent healthcare-related interactions that can interfere with patient well-being. In this review, we examine several manifestations of time toxicity in non-Hodgkin lymphoma and multiple myeloma and discuss their impact on decision-making with patients. For example, time toxicity may influence the choice of chemoimmunotherapy versus lenalidomide-rituximab in follicular lymphoma. In myeloma, it may inform the optimal dosing schedule for proteasome inhibitors and bisphosphonates. In both malignancies, varying time toxicity profiles are a key distinction between chimeric antigen receptor T-cell therapies and bispecific antibodies. We outline the challenges with measuring time toxicity as a trial endpoint but discuss its importance as a consideration for patient care, both in standard-of-care settings and in clinical trials. Throughout the review, we highlight strategies to lower the time toxicity of therapies in lymphoma and myeloma without compromising their efficacy or patient safety.
- 15 May 2024
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 65 (10) , 1418-1429
Mitigating time toxicity in lymphoma and multiple myeloma
The concept of time toxicity in oncology refers to the presence of frequent healthcare-related interactions that can interfere with patient well-being. In this review, we examine several manifestations of time toxicity in non-Hodgkin lymphoma and multiple myeloma and discuss their impact on decision-making with patients. For example, time toxicity may influence the choice of chemoimmunotherapy versus lenalidomide-rituximab in follicular lymphoma. In myeloma, it may inform the optimal dosing schedule for proteasome inhibitors and bisphosphonates. In both malignancies, varying time toxicity profiles are a key distinction between chimeric antigen receptor T-cell therapies and bispecific antibodies. We outline the challenges with measuring time toxicity as a trial endpoint but discuss its importance as a consideration for patient care, both in standard-of-care settings and in clinical trials. Throughout the review, we highlight strategies to lower the time toxicity of therapies in lymphoma and myeloma without compromising their efficacy or patient safety.
- 23 February 2024
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 24 (7) , 446-454.e3
Financial Toxicity, Time Toxicity, and Quality of Life in Multiple Myeloma
- 23 February 2024
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 24 (7) , 446-454.e3
Financial Toxicity, Time Toxicity, and Quality of Life in Multiple Myeloma
- 25 October 2023
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 21 (2) , 85-86
Digital symptom assessment tools: the next frontier in financial toxicity screening
- 25 October 2023
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 21 (2) , 85-86
Digital symptom assessment tools: the next frontier in financial toxicity screening
- Open Access
Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling Pathways
Immunotherapy has transformed lung cancer management, but PSC remains an aggressive subtype with a poor prognosis. This study investigates the differential expression of PD-L1 and alternative immune checkpoints (ICs; B7x, B7-H3, and HHLA2), and genetic alterations in PSCs. Tumor specimens of 41 PSC patients were evaluated. PD-L1, B7x, B7-H3, and HHLA2 were positive in 75.0%, 67.6%, 73.0%, and 91.9% of tumors, respectively. PD-L1 expression was significantly higher in the epithelial compared to the sarcomatoid component (median TPS: 50% vs. 0%, p = 0.010). Expression of PD-L1 in both components was only seen in 32.1% of patients. However, at least one IC was expressed in 92.9% of epithelial and 100% of sarcomatoid components. Furthermore, METex14 was detected in 19.5% of patients and was associated with a higher sarcomatoid percentage. Our preclinical studies revealed that METex14 induced PD-L1 expression via MAPK or PI3K/Akt pathways, and MET inhibitors decreased PD-L1 expression. Our findings demonstrate distinct expressions of ICs in PSC subcomponents. Thus, combination IC inhibition as a therapeutic strategy in PSC warrants further exploration. A high percentage of METex14 in PSC and its role in regulating PD-L1 expression reveal different therapeutic targets in this aggressive NSCLC subtype.
Open AccessHeterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling Pathways
Immunotherapy has transformed lung cancer management, but PSC remains an aggressive subtype with a poor prognosis. This study investigates the differential expression of PD-L1 and alternative immune checkpoints (ICs; B7x, B7-H3, and HHLA2), and genetic alterations in PSCs. Tumor specimens of 41 PSC patients were evaluated. PD-L1, B7x, B7-H3, and HHLA2 were positive in 75.0%, 67.6%, 73.0%, and 91.9% of tumors, respectively. PD-L1 expression was significantly higher in the epithelial compared to the sarcomatoid component (median TPS: 50% vs. 0%, p = 0.010). Expression of PD-L1 in both components was only seen in 32.1% of patients. However, at least one IC was expressed in 92.9% of epithelial and 100% of sarcomatoid components. Furthermore, METex14 was detected in 19.5% of patients and was associated with a higher sarcomatoid percentage. Our preclinical studies revealed that METex14 induced PD-L1 expression via MAPK or PI3K/Akt pathways, and MET inhibitors decreased PD-L1 expression. Our findings demonstrate distinct expressions of ICs in PSC subcomponents. Thus, combination IC inhibition as a therapeutic strategy in PSC warrants further exploration. A high percentage of METex14 in PSC and its role in regulating PD-L1 expression reveal different therapeutic targets in this aggressive NSCLC subtype.